```html

Mycobacterial Infections – A Complete Patient Guide

Overview

Mycobacterial infections are a group of diseases caused by bacteria of the genus Mycobacterium. The most well‑known member is Mycobacterium tuberculosis, the agent of tuberculosis (TB). However, “mycobacterial infections” also encompass a range of non‑tuberculous mycobacteria (NTM) such as M. avium complex (MAC), M. kansasii, and the rapid growers M. abscessus and M. fortuitum. These organisms share a thick, waxy cell wall that makes them resistant to many antibiotics and allows them to survive inside host cells.

Who it affects

• Adults age 25‑64 represent the majority of TB cases worldwide, but NTM infections are increasingly seen in older adults (≥ 65 years) and people with chronic lung disease.
• People with weakened immune systems—HIV infection, organ‑transplant recipients, patients on long‑term steroids or biologic agents—are at higher risk for both TB and NTM.
• Geography matters: TB is most prevalent in South‑East Asia, Africa, and the Western Pacific, accounting for ~10 million new cases each year (WHO, 2023). NTM disease is more common in high‑income countries where TB rates are low, with an estimated incidence of 5–10 cases per 100,000 people in the United States (CDC, 2022).

Symptoms

Symptoms vary widely depending on the specific mycobacterial species, the organ system involved, and whether the infection is acute or chronic. Below is a comprehensive list, grouped by the most commonly affected sites.

Pulmonary (Lung) Infection

• Chronic cough – lasting > 3 weeks, often productive.
• Hemoptysis – coughing up blood or blood‑streaked sputum.
• Shortness of breath – especially on exertion.
• Chest pain – usually pleuritic (sharp, worsens with breathing).
• Fever & night sweats – low‑grade fevers that may rise at night.
• Weight loss & fatigue – gradual, unintentional loss of 5–10 % body weight.
• Wheezing or crackles on auscultation.

Extrapulmonary Infection

• Lymphadenitis – swollen, tender lymph nodes, often in the neck (common in children with TB).
• Skin & soft‑tissue disease – nodules, ulcers, or sinus tracts, especially with rapid growers like M. abscessus.
• Bone & joint infection – joint pain, swelling, reduced range of motion; may mimic osteoarthritis.
• Disseminated disease – fever, chills, malaise, organomegaly; seen in severely immunocompromised patients.
• Gastrointestinal involvement – abdominal pain, diarrhea, weight loss (rare, mostly TB).
• Central nervous system – meningitis presenting with headache, neck stiffness, altered mental status (TB meningitis).

Causes and Risk Factors

Microbial causes

• Tuberculosis (TB) – caused by Mycobacterium tuberculosis. Transmitted person‑to‑person via airborne droplets.
• Non‑tuberculous mycobacteria (NTM) – over 190 species; most common disease‑causing NTM are MAC, M. kansasii, and the rapid growers (M. abscessus, M. fortuitum). NTM are environmental organisms found in soil, water, and biofilms; infection usually follows inhalation or direct inoculation.

Risk factors

• Living or working in congregate settings (prisons, shelters, nursing homes) – increased exposure to TB.
• Travel to high‑TB‑burden countries or immigration from such regions.
• HIV infection or CD4 count < 200 cells/µL – 20–30 × higher risk of active TB.
• Chronic lung disease (COPD, bronchiectasis, cystic fibrosis) – predisposes to NTM lung disease.
• Use of immunosuppressive drugs (corticosteroids, TNF‑α inhibitors, calcineurin inhibitors).
• Smoking, diabetes mellitus, malnutrition – all impair host defenses.
• Previous TB or NTM infection – can cause scarred airways that facilitate reinfection.

Diagnosis

Because mycobacterial infections mimic many other conditions, a systematic approach is essential.

Clinical evaluation

• Detailed history (exposures, travel, immune status).
• Physical exam focused on the symptomatic organ system.

Laboratory & imaging studies

• Sputum microscopy – Acid‑fast bacilli (AFB) stain (Ziehl‑Neelsen or Kinyoun) provides rapid presumptive evidence.
• Mycobacterial culture – Gold standard; liquid culture systems (e.g., MGIT) yield results in 7–21 days for TB, up to 6 weeks for NTM.
• Nucleic‑acid amplification tests (NAAT) – e.g., GeneXpert MTB/RIF detects TB and rifampin resistance within 2 hours.
• Line‑probe assays & whole‑genome sequencing – Identify species and drug‑resistance mutations.
• Chest radiography – Cavitary lesions, upper‑lobe infiltrates (TB) or nodular bronchiectatic changes (NTM).
• High‑resolution CT (HRCT) – More sensitive for early NTM lung disease.
• Biopsy & histopathology – Granulomatous inflammation with caseation (TB) versus non‑caseating granulomas (NTM).
• Blood tests – Interferon‑γ release assays (IGRAs) for latent TB; HIV testing; CBC, ESR/CRP for inflammation.

Diagnostic criteria for NTM pulmonary disease (American Thoracic Society/IDSA 2020)

1. Clinical: pulmonary symptoms + appropriate radiologic findings.
2. Microbiologic: ≥ two positive sputum cultures, or one positive bronchial wash, or lung tissue with AFB and histology.

Treatment Options

Treatment is prolonged, often months to years, and must be individualized based on species, drug susceptibility, disease site, and patient tolerance.

First‑line therapy for active tuberculosis

Drug	Typical dose (adult)	Duration
Isoniazid (INH)	5 mg/kg (max 300 mg) daily	6 months (standard)
Rifampin (RIF)	10 mg/kg (max 600 mg) daily	6 months
Pyrazinamide (PZA)	15‑30 mg/kg daily	2 months
Ethambutol (EMB)	15‑25 mg/kg daily	2 months (or longer if resistance suspected)

Regimens are abbreviated as “HRZE” for the intensive phase, followed by “HR” for continuation. Drug‑resistant TB requires second‑line agents (fluoroquinolones, bedaquiline, linezolid, etc.) and therapy can extend to 18‑24 months (WHO, 2023).

Therapy for non‑tuberculous mycobacterial (NTM) disease

• MAC lung disease – A macrolide (azithromycin 500 mg three times weekly or clarithromycin 500 mg twice daily) + ethambutol + rifampin for ≥ 12 months after culture conversion.
• M. kansasii – Rifampin + isoniazid + ethyl‑l‑cysteine (or macrolide if resistance).
• Rapid growers (e.g., M. abscessus) – Often require intravenous amikacin + tigecycline or imipenem, followed by oral macrolide consolidation. Treatment courses may exceed 12 months.

Therapeutic drug monitoring (especially for aminoglycosides) and regular audiograms are recommended to reduce toxicity.

Adjunctive measures

• Corticosteroids – Beneficial in TB meningitis and pericardial TB to reduce inflammation.
• Surgical resection – Considered for localized cavitary TB or NTM disease refractory to medical therapy.
• Infection control – Airborne isolation (negative‑pressure rooms) for active pulmonary TB until sputum conversion.

Lifestyle & supportive care

• Nutrition: high‑protein diet, vitamin D supplementation (800‑1000 IU/day) shown to improve immune response.
• Smoking cessation – improves sputum clearance and treatment success.
• Adherence support – Directly observed therapy (DOT) for TB; pill boxes or digital reminders for NTM.

Living with Mycobacterial Infections

Managing a chronic mycobacterial infection requires a blend of medical care, self‑monitoring, and lifestyle adjustments.

Medication adherence

• Set a fixed daily time (e.g., with meals) and use a medication diary.
• Report side effects early—hepatotoxicity from INH/RIF, optic neuritis from EMB, or hearing loss from aminoglycosides.

Monitoring symptoms

• Track cough frequency, sputum volume, fever, weight, and energy levels.
• Weigh yourself weekly; a loss > 5 % signals possible disease activity.

Pulmonary hygiene

• Chest physiotherapy, incentive spirometry, and regular aerobic exercise improve mucus clearance.
• Vaccinations: yearly influenza, pneumococcal (PCV20 or PCV15 + PPSV23), and COVID‑19 boosters.

Psychosocial support

• Join support groups (local TB societies, online NTM forums).
• Seek counseling if stigma or anxiety interferes with treatment.

Follow‑up schedule

• TB: sputum culture at 2, 4, and 6 months; liver function tests every 2 months.
• NTM: sputum cultures every 1–3 months until conversion, then quarterly for a year.

Prevention

• Vaccination – BCG vaccine provides variable protection against severe TB in children; not routinely used in the U.S. but recommended in high‑burden countries.
• Infection‑control practices – Wear N95 respirators when caring for patients with active pulmonary TB; ensure proper ventilation in congregate settings.
• Screening & treatment of latent TB infection (LTBI) – IGRA or tuberculin skin test followed by 3‑month weekly isoniazid‑rifapentine (3HP) regimen for those at high risk.
• Environmental measures for NTM – Use sterile water for respiratory equipment (e.g., nebulizers), avoid hot‑tub exposure if you have bronchiectasis, and regularly clean showerheads.
• General health maintenance – Control diabetes, maintain healthy weight, quit smoking, and limit alcohol consumption.

Complications

If left untreated or inadequately treated, mycobacterial infections can lead to serious sequelae.

• Pulmonary – Massive hemoptysis, bronchiectasis, fibrotic scarring, or progression to multidrug‑resistant TB.
• Disseminated disease – Miliary TB affecting liver, spleen, bone marrow; high mortality in HIV patients.
• Central nervous system – TB meningitis can cause hydrocephalus, seizures, and permanent neurologic deficits.
• Cardiovascular – Pericardial TB leading to constrictive pericarditis.
• Bone & joint – Joint destruction, spinal instability (Pott disease).
• Drug toxicity – Hepatotoxicity, optic neuritis, ototoxicity, and peripheral neuropathy may necessitate regimen changes.

When to Seek Emergency Care

---

Sources: World Health Organization. Global Tuberculosis Report 2023; Centers for Disease Control and Prevention. NTM Disease (2022); Mayo Clinic. Tuberculosis (2024); CDC. Latent TB Infection Treatment Guidelines (2023); American Thoracic Society/Infectious Diseases Society of America Guidelines for NTM (2020); NIH National Library of Medicine. Drug‑Induced Liver Injury (2023).

```